GSK and Cellzome Announce Alliance over Kinase Technology

This post was commissioned on September 10, 2008, and it was categorized as License/Partnership.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads(TM), a proprietary technology for screening and profiling kinases in relevant cells and tissues.

Under the agreement GSK has exclusive options to license drug candidates from Cellzome’s kinase programs directed against four identified targets, and three additional targets to be jointly identified by both parties. Cellzome will develop the most promising product candidates through to completion of a clinical proof of concept trial, unless GSK elects to exercise its option earlier. Upon Cellzome’s achievement of clinical proof of concept for a product candidate for a particular kinase target, GSK would have an exclusive option to license all product candidates from that program. GSK would then assume full responsibility for further clinical development and commercialization on a worldwide basis. Cellzome retains the right to continue the development and commercialization of drug candidates if GSK chooses not to exercise its option to that program.

Under the terms of the agreement, Cellzome will receive upfront payments of $25.2M upfront comprised of both cash and equity. Cellzome is eligible for up to $207M million per program in potential development, regulatory and commercial milestones and up to double digit royalties on net sales of products resulting from the alliance.

Theoretically Related Posts

February 6, 2009 -- Idenix Take $34M Upfront From GSK For IDX899 (0)
October 23, 2008 -- GlaxoSmithKline and AFFiRiS Ink Alzheimer’s Disease Vaccine Deal (0)
June 10, 2008 -- Big Pharma Tries to Shake Things Up (1)
February 18, 2009 -- Lilly Taps NeuroSearch For Preclinical Discovery Deal (0)
December 17, 2008 -- GlaxoSmithKline and Dynavax announce worldwide strategic alliance (0)
December 12, 2008 -- BMS Drops 240M For Codevelopment of 2 Exelixis Cancer Drugs (1)
November 24, 2008 -- Exelixis and Bristol-Myers Squibb to Co-Develop a Selective Cdc7 Inhibitor (2)
November 10, 2008 -- BTG Inks $320 Million Preclinical Deal With Onyx (0)
October 30, 2008 -- EMD Serono Snags US license for Tesamorelin From Theratechnologies (0)
October 30, 2008 -- GlaxoSmithKline to acquires Genelabs Technologies for $57M (0)

This post was constructed by

Eben Tessari

.

Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

If one were so inclined, one could follow him at any of these fine web 2.0 establishments: